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Electric tissue syntrophin, originally described as 
an M, 58,000 postsynaptic  protein  having  homologs in 
mammalian  muscle,  was  previously  shown  to  associate 
with  dystrophin  in  Triton  extracts  of lbrpedo postsyn- 
aptic  membranes.  It  also  associates  with  the lbrpedo M, 
87,000 postsynaptic  protein (87K), the  core  of  which is a 
superdomain  homologous  to  the  cysteine-rich (CR) and 
COOH-terminal (CT) domains  of  human  dystrophin. Us- 
ing  immunoaffinity  purifications  from  various  rat tis- 
sues  and  immunoblotting,  we  find  that  syntrophin  asso- 
ciates  with  dystrophin,  utrophin  (the  chromosome 
6-encoded  dystrophin  homolog  formerly known as dys- 
trophin-related protein), multiple proteins which are 
cross-reactive with 8% and two subfamilies of 71K- 
like proteins (CRCT-containing proteins encoded by 
the  dystrophin  gene  under  the  control of an  alternative 
promoter in intron 62). One 71K subfamily  retains  the 
dystrophin  COOH-terminal  sequence;  the  other  has  an 
alternative COOH-terminal sequence caused by dele- 
tion of the penultimate exon by alternative splicing. 
The relative  masses of the  members  of  the  subfamilies 
suggest  they  arise by alternative  splicing  at  other  pre- 
viously  described sites within CT. These  results  estab- 
lish  that  syntrophin is a  general  ligand  for  the CRCT 
domain in mammalian dystrophin and its homologs. 
They also reveal a greater diversity in 71K proteins 
than  has  previously  been  apparent. 
Dystrophin, the protein product of the Duchenne muscular 
dystrophy gene, is  a member of the  spectrida-actinin family of 
actin-binding proteins. Although this affiliation alone would  be 
likely to assure  a wide distribution, the degree to which  dys- 
trophin and  related proteins are widely distributed over tissues 
and often interestingly distributed on  cell surfaces has proven 
surprising. The products of the dystrophin gene are also re- 
markably varied and include short forms of a sort unknown in 
other branches of the  spectrida-actinin family. This family has 
recently been characterized as being  more subject to alterna- 
tive splicing than any other cytoskeletal family (Ahn and 
Kunkel, 1993). The functions of most of these products are 
totally unknown. However, their wide distribution suggests ap- 
propriate studies in almost any  tissue could potentially aid in 
identifying those functions and in explaining why quantitative 
or qualitative deficiencies in dystrophin are catastrophic for 
muscle  cells. 
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The full-length forms of the dystrophin family are dystrophin 
(Hoffman et al . ,  1987) and utrophin (previously known as dys- 
trophin-related protein, or DRP Love et al., 1989; Khurana et 
al.,  1990). Dystrophin is expressed principally in the three 
muscle types and  in  brain (Hoffman et al., 1987;  Chelly et al., 
1988). Utrophin is encoded by a  separate gene and  is expressed 
in most tissues, although at low levels in normal skeletal 
muscle (Khurana et al., 1990; Love et  al., 1991). These large 
peripheral membrane proteins proteins have an NH2-terminal 
actin binding domain, a  central rod  region containing 24 (22 in 
utrophin) spectrin-like triple helical repeats; a cysteine-rich EF 
hand-containing third domain (CR)’ with homology to the 
COOH-terminal domain of Dictyostelium a-actinin, and a 
COOH-terminal domain (CT) without homology to proteins 
outside the dystrophin subfamily  (Koenig et al., 1988;  Davison 
and Critchley,  1988;  Tinsley et al., 1992). Dystrophin is shown 
schematically in Fig. 1. In skeletal muscle, dystrophin and 
utrophin are associated with a complex of transmembrane gly- 
coproteins, including an extracellular laminin-binding protein 
(Ervasti et al., 1990; Yoshida and Ozawa, 1990; Ibraghimov- 
Beskrovnaya et al., 1992; Matsumura et al., 1992). The CRCT 
domain,  which is highly conserved  across  species in both dys- 
trophin and utrophin (Lemaire et aE., 1988; Love et al., 19911, is 
believed to contain the glycoprotein binding site (Suzuki et al., 
1992). Thus, dystrophin and utrophin appear to be  long  flexible 
bridges between the extracellular matrix and the actin-based 
cytoskeleton.  Although the exact roles of these proteins have 
not  been determined, they are believed to be  involved in me- 
chanical stabilization and molecular organization of the plasma 
membrane and cell  cortex and possibly in regulation of calcium 
channel activity (reviewed in Lansman and Franco, 1991 and 
in Ahn and Kunkel, 1993). 
The known normally occurring short forms in  this family 
include several which are encoded by the dystrophin gene plus 
an M, 87,000 phosphoprotein (87K) first identified in electric 
tissue of electric rays  (Carr et al., 1989). All are based on the 
cysteine-rich (CR) and COOH-terminal (CT) domains (see Fig. 
1). Of those encoded by the dystrophin gene, the only  one to 
have been  fully  sequenced is  a 71K protein expressed under the 
direction of an internal promoter lying between  exons  62 and 
63 (Lederfein et al., 1992; Rapaport et al., 1992). It has  a core 
domain containing 583 out of the 610 amino acids of the CRCT 
superdomain flanked by unique N H 2 -  and COOH-terminal se- 
quences. The latter  arises by excision of the penultimate exon 
of dystrophin, resulting in  a shift of the reading frame (Bar et 
al., 1990). In  this paper, we call this  the “71Kfounder sequence” 
because of its primal role in defining the 71K family (Bar et al., 
1 The abbreviations used are: CR and CT, the cysteine-rich and 
COOH-terminal domains of dystrophin and homologous  sequences; Ab, 
rabbit  polyclonal  antibody; mAb, mouse  monoclonal  antibody; 87K, the 
87-kDa  postsynaptic  protein described by Cam et al. (1989); 71K, the 
sequence described by Lederfein et al. (1992) and  related  sequences. 
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FIG. 1. Schematic representation of dystrophin  and  related 
proteins (from Koenig et ul. (1988) and Koenig and Kunkel 
(1990)). A B ,  actin binding domain; rounded rectangles, spectrin-like 
triple helical repeats. Black rectangles, hinge regions. CR, cysteine-rich 
domain. CT, COOH-terminal domain. Utrophin would be represented 
like dystrophin but with a slightly shorter repeat region. The 71K 
founder sequence is  the sequence of Lederfein et al. (1992); it  has a 
unique COOH-terminal. The  other form of  71K shares NH2 and COOH 
termini with the founder sequence and dystrophin, respectively. The 
NH2- and COOH-terminal sequences of the 87K protein are unique; the 
latter can be phosphorylated. For other  details,  see text. 
1990; Rapaport et al., 1992; Lederfein et  al., 1992). It is believed 
to be encoded by a 6.5-kilobase transcript. In addition, recent 
immunoblotting (Cox et al., 1993) and partial sequencing of a 
4.8-kilobase transcript (Blake et al., 1992) have suggested the 
existence of forms which are similar but  retain  the dystrophin 
COOH-terminal sequence (Fig. 1). All of these  shorter forms 
may also occur in multiple isoforms, since the CT domain is 
subject to extensive alternative splicing (Feener et al., 1989; 
Bies et  al., 1992). 
The 87K protein is a component of acetylcholine receptor-rich 
postsynaptic membranes from electric tissue (Cam et al., 1989). 
It  has a core domain of 547 amino acids which has modest, but 
clear, homology to the dystrophin CRCT superdomain. Inter- 
estingly, its 150-amino acid COOH-terminal sequence, which is 
not homologous to any known sequence, is subject to tyrosine 
and serine phosphorylation by kinases endogenous to the post- 
synaptic membranes (Wagner et al., 1993; Fig. 1). Anti-87K 
antibodies label rat skeletal muscle at  the neuromuscular junc- 
tion and on the extrajunctional sarcolemma (Carr et  al., 1989), 
suggesting the existence of a mammalian 87K  homolog distrib- 
uted  in muscle very  much like dystrophin. 
To understand the functions of the long and  short forms of 
the dystrophin family, it will be essential to identify all the 
proteins with which they associate. Electric tissue of electric 
rays contains an M, 58,000 protein (58K)  which was originally 
identified as a cytoplasmic  component of acetylcholine receptor- 
rich domains in electric tissue and cultured skeletal muscle 
(Froehner et al., 1987). With the development of  our knowledge 
of dystrophin, it became apparent  that many features of the 
distribution of  58K in muscle  cells are shared with dystrophin 
(see “Discussion”). The protein was then shown by biochemical 
means to associate with both dystrophin and  the 87K protein in 
Triton extracts of electric tissue membranes (Butler et  al., 
1992). These results suggested that 58K, whose mammalian 
homologs are widely expressed in muscle and non-muscle tis- 
sues (Froehner et al., 1987; Adams et al., 1993) could be a 
general ligand for dystrophin and  related proteins. In  this pa- 
per, we show that 58K  does in fact associate with mammalian 
dystrophin, utrophin, and multiple short CRCT-containing  ho- 
mologs. Because it accompanies all known proteins of the dys- 
trophin family which have been tested, Adams et al. (1993) 
have given to 58K the name “syntrophin” (from crvvrp~as, 
companion, associate). 
MATERIALS AND METHODS 
Monoclonal  Antibodies 
Anti-dystrophin mAbs-Monoclonal (mAb) 1808DYS was raised 
against lbrpedo dystrophin in  the Froehner laboratory and shown to 
recognize mammalian dystrophin specifically; it was previously desig- 
nated mAb 1808 (Sealock et al., 1991). NCGDYS2 (also designated 
Dy8/6C5; purchased from Vector Laboratories) was raised against a 
peptide corresponding to the  last 17 amino acids of human dystrophin 
(Nicholson et al., 1992). NCGDYSl (also designated Dy4/6D3;  Vector) 
recognizes the central rod region of dystrophin (Nicholson et al., 1990). 
MANDRAl (a generous gift of G.  E. Morris) reacts within the COOH- 
terminal domain of dystrophin (Nguyen thi Man et al., 1992) and  has 
been shown to recognize the 71K founder sequence (Lederfein et al., 
1992). It does not recognize utrophin. 
Anti-syntrophin-mAb  1351SYN was raised  against lbrpedo syntro- 
phin (Froehner et al., 1987; originally identified as mAb 1351) but 
shows broad cross-species reactivity (Froehner et al., 1987; Chen et al., 
1990; Adams et al., 1993). 
Anti-87K-mAb 13H1 (a generous gift of J. B. Cohen) was raised 
against lbrpedo 87K and shown by immunofluorescence to recognize a 
protein of the sarcolemma and the neuromuscular junction in  rat and 
chick skeletal muscle (Carr et al., 1989). 
Anti-actin-The pan-actin antibody was obtained from Boehringer 
Mannheim. 
Peptides a n d  Polyclonal  Antibodies 
Polyclonal antibodies (Abs) against high performance liquid chroma- 
tography-purified synthetic peptides (Multiple Peptide Systems) were 
prepared in rabbits according to standard methods. Ab  UTR3165 was 
raised  against the peptide SMWPEHYDPSC (amino acids 3165-3174  of 
human utrophin plus a COOH-terminal Cys;  Love et al., 1989; Tinsley 
et al., 1992). Ab 7lKnt was raised against REHLKGHEC (the @ermi- 
nal sequence encoded under the control of the alternative promoter in 
intron 62). Ab 7lKFSct was raised against CGRAMESLVSVMT- 
DEEGAE (the 71K founder sequence erboxy-terminal plus an NH2- 
terminal cysteine). Antibodies in antiserum UTR3165 were affinity- 
purified by standard methods using Afli-Gel 15-coupled SMWPEH- 
YDPSC. The IgG fraction of serum  7lKFSct was prepared by ammo- 
nium sulfate fractionation and DEAE chromatography (Fujiwara and 
Pollard, 1976) and coupled to Sepharose as described (Butler et al., 
1992). Each of these antibodies was shown to be a specific  probe  on blots 
by competition experiments in which incubation with the appropriate 
peptide, but not an inappropriate peptide, eliminated immunoreactiv- 
ity. 
Zmmunoafinity Purifications 
Frozen tissues  (5 g) were homogenized 30 s in a Polytron homog- 
enizer in 50 ml of  ice-cold 10 m~ sodium phosphate, 5 m~ EDTA,  0.4 M 
NaCl, pH  7.8, containing protease inhibitors (Sigma; aprotinin, leupep- 
tin,  and  aprotinin at  0.5 pgml each, pepstatin A, 0.05 pdml, and 2 r n ~  
phenylmethylsulfonyl fluoride). ARer centrifugation (10 min at  12,000 x 
g),  the pellet was rehomogenized, centrifuged, and resuspended in 15 
ml of buffer. Proteins were solubilized by addition of Triton X-100 
(Pierce Chemical Co.) to 1%, incubation on ice 15 min, and centrifuga- 
tion. Extracts were subjected to immunoaffinity purifications on Sepha- 
rose-bound antibodies and the resulting fractions prepared for  electro- 
phoresis as described previously (Butler et al., 1992). For control 
preparations,  resins were coupled to a monoclonal antibody of unrelated 
specificity. 
Torpedo dystrophin was immunoaffinity purified from electric organ 
postsynaptic membranes as described (Butler et al., 1992). 
Gel Electrophoresis a n d  Zmmunoblotting 
For Coomassie Blue staining  and blotting, standard Laemmli SDS 
gels contained 8% acrylamide and 0.13% bisacrylamide (0.04% bisacryl- 
amide when blotting dystrophin or utrophin). Prestained molecular 
weight standards (Sigma) were calibrated with normal standards 
(Sigma). Proteins and prestained standards were transferred to Im- 
mobilon P (Millipore) in 25 m~ Tris, 192 m~ glycine in a semidry 
apparatus (Bio-Rad). Blots were blocked with 5% milk protein, then 
probed by standard methods. The alkaline phosphatase-conjugated sec- 
ond antibodies (Jackson ImmunoResearch) were revealed with Western 
Blue (Promega). 
RESULTS 
Syntrophin Associates with Llystrophin and Utrophin--To 
identify proteins with which mammalian syntrophin may be 
associated, we immunopurified syntrophin from Triton X-100 
extracts of crude particulate fractions of various rat tissues 
using Sepharose-bound anti-syntrophin mAb  1351SYN.  Upon 
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hc. 2. Co-purification of dystrophin and utrophin  with syn- 
trophin. A, Coomassie Blue-stained gel of syntrophin preparations 
from Torpedo electric tissue ( T )  and rat skeletal muscle (Sk), cardiac 
muscle (C), stomachkmooth muscle (Srn), brain (Br),  lung (Lu), liver 
(Li), kidney (K), and testis (Te). The positions of dystrophin and utro- 
phin ( D I U ) ,  Torpedo 87K and lbrpedo syntrophin (Syn)  are indicated. 
Molecular mass markers are indicated on the left. Proteins that were 
major species in both the initial  extracts and control preparations are 
designated M (putative myosin, in  the  three muscle preparations), A 
(actin, in  the muscle and kidney preparations), and L (in liver). Molecu- 
lar weight markers are indicated on the left. lbrpedo syntrophin, origi- 
nally identified as a 58K protein (Froehner et al., 1987), in fact migrated 
as  an M ,  53,000 protein; similar low values have been found by others 
(Carr et al., 1989; Chen et al., 1990). B-D, immunoblots of syntrophin 
preparations probed for syntrophin with mab 1351SYN (B) ,  for dystro- 
phin with mab 1808DYS (C), and for utrophin with Ab  UTR.3165 0 ) .  
denaturing gel electrophoresis and Coomassie staining,  the re- 
sulting  preparations gave one or more  major bands at the po- 
sition expected for syntrophin (“Syn” in Fig. 2.4) and at the 
position (Dm) of dystrophin and  utrophin (which are not dis- 
tinguishable  in  our gel system),  plus  other bands. Only three 
major  proteins (M, A, and L in Fig. 2 A )  could be readily  iden- 
tified as nonspecific components, since they were  also present 
in control preparations  (see “Materials and Methods”) and were 
major  proteins in  the  starting  extracts. M is presumably myo- 
sin,  and A is presumably  actin;  immunoblotting with a pan- 
actin monoclonal antibody confirmed the presence of actin at 
the  appropriate M, in all preparations  (not shown). Liver pro- 
tein L was  not identified. 
Immunoblotting  with mAb 1351SYN confirmed the presence 
of syntrophin  in all the  preparations, as expected (Fig. 2B). 
Typically, it occurred in two, and sometimes more, closely 
spaced bands (cf.  also Froehner et al., 1987). This multiplicity 
is consistent with the  results of  cDNA sequencing by Adams et 
al. (19931, who have identified two forms of mammalian syn- 
trophin (syntrophin-1 and -2) encoded by separate genes. Since 
we had no way of linking  bands to specific sequences, all mAb 
1351SYN-reactive species have been taken  together as syntro- 
phin  in  this paper. 
Blotting  with anti-dystrophin mAb  1808DYS (Butler et al., 
1992) showed strong reactivity in  preparations from skeletal, 
cardiac, and smooth muscle and weak  reactivity in  lung (Fig. 
2C). Preparations from brain, liver, kidney, and testis were 
essentially  negative with  this antibody. Anti-dystrophin mAbs 
DYS2 and MANDRAl (see “Materials and Methods”) gave 
similar results. The antibody DYS1, against  the  central rod 
region of dystrophin,  detected  weak  reactivity in  preparations 
from brain  (not shown). The low amounts  in  preparations from 
brain  may be due to localization of brain dystrophin in post- 
synaptic  densities (Lidov et al., 1990, 1993; Kim et al., 19921, 
which are a detergent-resistant fraction. None of the antibodies 
detected  dystrophin in control preparations  (data not shown). 
In  the reverse  experiment, mAb 1808DYS-purified dystrophin 
from rat skeletal, cardiac, and smooth muscle contained syn- 
trophin  (not shown), as previously found with Torpedo dystro- 
phin from electric tissue postsynaptic membranes  (Butler et al., 
1992). Syntrophin is thus associated with dystrophin in ex- 
tracts of all three types of rat muscle. 
Blots were probed for utrophin using polyclonal antibody 
(Ab) UTR3165, raised  against a peptide specific to the  utrophin 
CT domain. Utrophin was readily  detected in  all  rat syntrophin 
preparations, although the  amounts were low in  preparations 
from skeletal and cardiac muscle and from brain (Fig. 2 0 ) .  
Utrophin could not be detected in control preparations. Ab 
UTR3165 was specific for utrophin, since its reactivity was 
blocked by preincubation with 2.5 peptide antigen, and it 
failed to  react with mAb 1808DYS-purified dystrophin from all 
three muscle types (data not shown). These results suggest that 
syntrophin  associates  with utrophin  in  extracts of normal  skel- 
etal, cardiac, and smooth muscle and of several non-muscle 
tissues. The  failure of ab UTR3165 to label  dystrophin  prepa- 
rations also suggests  that dystrophin and  utrophin do not form 
heterocomplexes, even when one is  present  in excess over the 
other  (skeletal  and smooth muscle; cf. Figs. 2, C and D; Chelly 
et al., 1988; Nguyen thi Man et al., 1992). 
Syntrophin Associates with Multiple 7lK-like Proteins-The 
syntrophin preparations contained  proteins which appeared to 
correspond to many of the  short CRCT-containing alternative 
products of the dystrophin gene. The anti-dystrophin mAb 
MANDRAl detected prominent bands in the region of M, 
70,000-80,000 in  preparations from all rat tissues, although in 
lower amounts  in  the  skeletal muscle preparation (Fig. 3A).  
These  characteristics mimic those described for the 71K foun- 
der sequence in whole tissue  samples  and  that protein is known 
to be recognized by MANDRAl (Lederfein et al., 1992). Except 
in the preparations from skeletal muscle, 71K-like proteins 
were  also  detected by  Ab 71Knt, raised  against a peptide hav- 
ing  the 71K NH2-terminal sequence (Fig. 3B). Reactivity was 
essentially  eliminated by prior  incubation of the antibody with 
the amino-terminal  peptide (25 UM), but not by incubation  with 
a control peptide (the COOH-terminal peptide of the 71K foun- 
der sequence; data not shown). Neither Ab 71Knt nor MAN- 
DRAl reacted detectably with blots of control preparations. 
Kidney syntrophin preparations contained a low molecular 
weight Ab 71Knt-reactive form not recognized by  MANDRAl 
(cf. Fig. 3, A and B, lane K); whether  this  is a new  form or a 
proteolytic fragment is not known. 
Blots were  also probed with Ab 7lKFSct,  raised  against a 
peptide  corresponding to the COOH-terminal18  amino  acids of 
the 71K founder sequence. Although this antibody detected 
71K-like proteins in  preparations from all the  tissues,  these 
proteins unexpectedly constituted only a high molecular mass 
subpopulation of the MANDRAl- and Ab 71Knt-positive pro- 
teins  in  the 71K region (not shown). To facilitate comparison, 
Ab 71KFSct-reactive proteins  were purified from a liver extract 
using a Sepharose-bound IgG fraction, then electrophoresed 
next to a mAb 1351SYN-purified liver syntrophin  preparation 
and blotted. The two preparations appeared to contain the 
same  subset of proteins when probed by ab 71KFSct, as ex- 
pected if all the Ab 71KFSct-reactive forms in liver  also asso- 
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Frc. 3. A and B, co-purification of 71K-like proteine with syn- 
trophin. Syntrophin  preparations  were probed for 71K-like proteins 
with  anti-dystrophidanti-71K mAb "IRA1 (A) and  with Ab 71Knt, 
raised  against  the NH,-terminal sequence common to  all known 71K 
proteins ( B ) .  Only the 71K regions of the blots are shown. C, compari- 
son of 71K-like proteins  in  liver  syntrophin  preparations  with  founder 
sequence-like 71K proteins  directly  purified from liver. In each  pair, the 
left lane shows the liver  syntrophin  preparation;  the right lane shows 
71K proteins purified with Ab 7lKFSct, raised against the founder 
sequence COOH-terminal. The blots were probed with Ab 7lKFSct 
(abbreviated  FSct),  the  anti-dystrophin CT domain MANDRAl (MAN), 
Ab 71Knt. and mAb  DYSP, which recognizes the  last 17 amino  acids of 
dystrophin. 71K-like proteins  having  the  founder sequence-specific and 
dystrophin-specific COOH termini form distinct subpopulations. D, 
syntrophin  preparations from all  tissues  were probed for 71K proteins 
having the  dystrophin  COOH-terminal  with mAb DYS2. Readily de- 
tectable or strong  signals  were  obtained from all the  mammalian  tis- 
sues  except kidney. E ,  co-purification of syntrophin  with 71K founder 
sequence-like  proteins. 71K proteins  in  liver  extracts  repurified on af- 
finity  resins  made  with Ab 71KFSct in  the presence  (lanes  indicated "+") 
or absence  (lanes  indicated "-"I of 25  founder  sequence COOH- 
terminal  peptide.  Blots  were probed for 71K-like proteins  with MAN- 
DRAl (MAN) and Ab 71KFSct  (abbreviated  FSct),  and  for  syntrophin 
with mAb 1351SYN (abbreviated 1351). Syntrophin co-purified with 
71K  proteins.  The co-purifiecation was specific, since  purifications in 
the presence of the peptide yielded undetectable  amounts (MAN) or 
barely  detectable  amounts  (7lKFSct, 1351SYiV) of antibody reactivity. 
Tissue  identifications  in A and D are  the  same as in  Fig. 2. 
ciate  with  syntrophin (Fig. 3C, lanes indicated 7IKFSct). How- 
ever, probing  with MANDRAl or the anti-71K NH2 terminus 
Ab 71Knt showed clearly that  the Ab 71KFScbpurified sample 
contained only a subset of the 71K-like proteins found in  the 
syntrophin sample (Fig. 3C, lanes MAN and 7lKnt, respec- 
tively). This  subset could usually be resolved into two bands 
running at apparent M, 80,000 and 77,000 in  our gels. To ex- 
plore the possibility that  the Ab 71KFSct-negative forms could 
be 71K-like proteins that  retain  the dystrophin COOH-termi- 
nal sequence, blots were probed with mab DYS2, a commer- 
cially available  antibody raised  against  the  last 17  amino  acids 
of dystrophin (see "Materials and Methods"). This antibody 
should  not react with the 71K founder  sequence, and  the Ab 
71KFSct-purified proteins were in fact  not  labeled,  although a 
minor band not coincident with ab 71KFSct-labeled protein 
was detected (Fig. 3C, right lane under DYS2). In  the syntro- 
phin  preparation, however, DYSB recognized a number of pro- 
teins of approximate M, app ranging from 80,000 to 71,000 (Fig. 
3C, left lane under DYS2). The envelope of proteins labeled 
with DYSB corresponded closely with  those labeled by MAN- 
DRAl and Ab 7lKnt,  eliminating  the possibility that  the mul- 
tiplicity arose by proteolytic nicking. The observed range of 
molecular masses  is compatible with the several alternative 
splices in CT which have  already been described (Feener et al., 
1989; Bies et al., 1992). When discrete bands were resolved on 
immunoblots, four or five bands could typically be discerned 
(not explicitly shown). Liver therefore appears to contain a 
large population of 7lK-like, syntrophin-associated proteins 
encoded by the dystrophin  gene under  the control of the pro- 
moter located between exons 62 and 63, but  retaining  the dys- 
trophin COOH-terminal sequence. While this  manuscript was 
in  preparation, Cox et al. (1993) also reported that DYSB rec- 
ognizes 71K-like proteins on immunoblots. 
Multiple DYS2-reactive bands were found in  the 71K region 
in  the syntrophin preparations from all the tissues studied, 
including skeletal muscle. Only in kidney  were very weak sig- 
nals obtained  (Fig. 30). In view of these  results, we attach  little 
significance to the  failure of ab 71Knt to detect 71K-like pro- 
teins  in  skeletal muscle (Fig. 3B). That antibody typically gives 
a weak  immunoblot signal,  and  the  amounts of material from 
skeletal muscle we were able to apply to the gels was limited. 
On the  other  hand,  the ase with which we could detect 71K- 
like  proteins in  skeletal  and cardiac muscle tissues using DYS2 
and MANDRAl appeared to be at variance  with the impression 
given by several studies of  mRNA levels that 71K proteins are 
expressed at extremely low levels in  adult  skeletal muscle tis- 
sue, although they are abundant in fetal muscle. However, 
whether the skeletal muscle 71K-like proteins we identified 
were  products of muscle cells or of non-muscle components of 
the  tissues  is  not known. 
Whether electric tissue contains 71K-like proteins is un- 
known. However, the  failure of Torpedo preparations to react 
with DYS2 (Fig. 30, lanes T )  is without significance, since the 
COOH-terminal sequence of Torpedo dystrophin is substan- 
tially  different from that of mammalian dystrophin (Yeadon et 
al., 1991). 
To determine  whether  the co-purification of 71K founder se- 
quence-like proteins and syntrophin  was specific,  71K was pu- 
rified from liver extracts  using Ab 71KFSct as before, but in the 
presence and absence of the founder sequence COOH-terminal 
peptide. The product obtained in  the absence of the peptide was 
reactive with MANDRAl and Abs 71Knt and 7lKFSct and 
contained syntrophin (Fig. 3E, lanes indicated by ""7. The 
preparations done in  the presence of the peptide were negative 
for all these antibodies (lanes indicated by "+"). The co-purifi- 
cation was therefore specific. 
87K-like Proteins Co-purify with Syntrophin-All syntrophin 
preparations,  but no control preparations,  also contained reac- 
tivity to mAb 13H1, raised  against Torpedo 87K (Carr et al., 
1989). The reactive species (Fig. 4) occurred in a single band 
(liver, 62,000) or in multiple bands 83,000- 
46,000). Multiple mAb 13H1-reactive bands were also observed 
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FIG. 4. Co-purification of 87K-like  proteins with syntrophi. 
Syntrophin preparations from tissues  (see Fig. 2) were probed with mAb 
13Hl, raised against the Torpedo 87K protein. One or more strong 
signals were obtained from all tissues. Torpedo 87K protein is indicated. 
in  preparations from electric tissue.  This could  possibly have 
been due to proteolysis during  preparation, since Carr et dl. 
(1987) noted that 87K was particularly  sensitive to proteolfisis. 
However, our anti-protease  mixture included the precautions 
suggested by Carr et al. (1987) plus additional ones (see "Ma- 
terials and Methods") and appeared to be adequate. It pro- 
tected dystrophin (known to be highly protease-sensitive; 
Koenig and Kunkel, 1990), since mAb  1808DYS detected only 
full-length forms on blots (Fig. 2 0 .  (mAb  1808DYS recognizes 
an extremely large population of dystrophin fragments in 
samples of Torpedo dystrophin which are known to have been 
proteolyzed).2 In addition, the lower molecular weight forms of 
Torpedo 87K in  our  preparations were minor components es- 
sentially undetectable on Coomassie-stained gels (Fig. 2A, 
lanes T ) .  Our  results, therefore, suggest that  the mAb 13H1- 
reactive proteins  in the  rat constitute a family of similar pro- 
teins  and  that most rat  tissues contain one or more members of 
the family. 
71K and 87K Proteins Form Independent Complexes with 
Syntrophin-To determine  whether the 71K- and 87K-like pro- 
teins could have occurred in  syntrophin  preparations indirectly 
via association with dystrophin, the syntrophin  preparations 
were compared to mAb 1808DYS-purified dystrophin. At simi- 
lar high  dystrophin loadings (Fig. 5 A ) ,  71K-like proteins (foun- 
der sequence type) and 87K-like proteins gave strong  signals  in 
skeletal, cardiac, and smooth muscle syntrophin  preparations, 
but could not (71K, Fig. 5B) or could barely (87K; Fig. 5C) be 
detected in  the corresponding dystrophin preparations. A simi- 
lar  result was obtained with electric tissue postsynaptic mem- 
branes  (Butler et al., 1992), where syntrophin-87K co-purifica- 
tion via independent association with a third, non-dystrophin, 
protein was rendered unlikely by the simple protein composi- 
tion of the final product. Syntrophin thus  appears to interact 
directly with both the 71K- and 87K-like proteins in  extracts of 
rat muscle. 
DISCUSSION 
We have shown that dystrophin and 71K founder sequence- 
like proteins co-purify with  syntrophin from Triton extracts of 
several rat  tissues and that syntrophin co-purifies with dystro- 
phin and with 71K. Utrophin, 71K-like proteins which appear 
to retain the dystrophin COOH-terminal sequence, and pro- 
teins immunologically related to the 87K phosphoprotein of 
electric tissue also co-purified with syntrophin, although in 
these cases we did not have the means to do the reverse puri- 
fications. None of these proteins was purified in significant 
quantity in control purifications. For utrophin, 71K founder 
sequence-like proteins, and 87K-like proteins, we documented 
that  the co-purification was independent of dystrophin. These 
results constitute  strong evidence that syntrophin associates 
* J. Holder and R. Sealock, unpublished observations. 
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FIG. 5. Failure of CRCT homologe to eo-purify with d y s b  
phin. Dystrophin (lanes marked Dys) was purified from extracts of rat 
skeletal (Sk), cardiac (C), and stomachlsmooth muscle (Sm)  using anti- 
dystrophin mAb  1808DYS and compared with the corresponding syn- 
trophin  preparations (Syn).  Blots were probed with mab MANDRAl for 
both dystrophin (A) and 71K ( B )  and with mAb 13Hl for 87K-like 
protein (C).  Unlabeled lanes, prestained standards. The 71K- and 87K- 
like proteins were significantly present only in  the syntrophin prepa- 
rations. 
directly with  all these proteins, suggesting that syntrophin is a 
general ligand of the CRCT superdomain in dystrophin and 
homologous proteins. Unfortunately, the information on sub- 
cellular distributions which is required as a first test for the in 
situ existence of these associations is available only for muscle. 
Dystrophin and syntrophin are both general sarcolemmal pro- 
teins  but are particularly concentrated at  the neuromuscular 
and myotendinous junctions  (Froehner et al., 1987; Chen et al., 
1990; Shimizu et al., 1989; Byers et al., 1991). Where it  has 
been examined, their distributions are co-extensive at  a very 
high level of detail (Kramarcy and Sealock, 1990; Bloch et al., 
1991). Syntrophin is also a sarcolemmal component in cardiac 
(Butler et al., 1992) and smooth muscle tissue: as  is dystro- 
phin. These results support in  situ association of syntrophin 
and dystrophin. 
Rabbit and mouse muscle dystrophins and mouse muscle 
utrophin are associated with a cytoplasmic 59K peripheral 
membrane  protein in addition to the glycoprotein  complex (Er- 
vasti et al., 1990;  Yoshida and Ozawa, 1990; Matsumura et al., 
1992). The 59K protein runs  as multiple bands on gels (Ervasti 
et al., 19911, and its concentration on sarcolemma is reduced in 
dystrophin-minus muscle (Ohlendieck and Campbell, 1991; 
Ohlendieck et al., 1993), although it remains concentrated at  
the neuromuscular junction (Matsumura et al., 1992). Syntro- 
phin shares  these properties (Froehner et al., 1987; Butler et 
al., 1992). These similarities suggest that  the 59K protein and 
syntrophin could be identical, but  this  has not been tested in 
any direct experiment. If they are identical, the speculative 
prediction of Ervasti  and Campbell (1991) that  the 59K protein 
associates with CRCT  will  prove to have been correct. 
The association of syntrophin  with CRCT has implications 
for the possible activities of the protein. A syntrophin molecule 
bound to CRCT  would lie near  the glycoprotein complex (Su- 
zuki et al., 1992), and could  possibly modulate the interaction of 
dystrophin with the complex. This could  be an important func- 
tion, since the complex is one, although not the only, membrane 
N. R. Kramarcy and R. Sealock, unpublished results. 
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binding site for dystrophin (Hoffman et al., 1991;  Helliwell et 
al., 1992; =can et al., 1992). This activity could  be general. The 
available evidence suggests that utrophin  and dystrophin as- 
sociate with the same glycoprotein complex in muscle (Mat- 
sumura et al., 1992). The 87K protein is membrane-bound, 
although its membrane receptor is unknown (Can- et al., 1989). 
And the proteins of the 71K family appear to be membrane- 
bound (they occur in particulate fractions and are solubilized 
by Triton; Lederfein et al., 1992; see “Materials and Methods”). 
The short forms are presumably bound to the membrane via 
the same glycoprotein  complex as dystrophin or a similar one. 
Although there  is presently no demonstrated reason for  which 
association of these proteins with thda glycoprotein  complex 
would require modulation (but see below), the facts that syn- 
trophin and  the 87K protein in electric tissue can be phosphory- 
lated by endogenous kinases (Wagner and Huganir, 1993; Wag- 
ner et al., 1993) and that recombinant CR binds Ca2+ 
(presumably on the EF hands; Milner et al., 1992) suggest that 
syntrophin-CRCT complexes are loci of regulatory activity. 
If dystrophin forms an antiparallel homodimer, as ultra- 
structural images (Sato et al., 1992) and analogy to spectrin 
suggest, CRCT-bound syntrophin on one dystrophin molecule 
would lie near to and could potentially modulate activity of the 
actin binding domain of the sister dystrophin molecule. This 
seems unlikely to be an obligatory activity, however, since at 
present  there is no  known  way to fit the short CRCT  homologs 
into such a scheme. 
The present  results provide a basis for interpretation of stud- 
ies of the possible involvement of syntrophin in acetylcholine 
receptor clustering (Froehner et al., 1987; Bloch et al., 1991; 
Froehner, 1993).  When  acetylcholine receptor clusters are in- 
duced on cultured Xenopus muscle  cells by application of latex 
beads, syntrophin appears at clusters on a far more rapid time 
course (a few hours versus a few days) and with a more  recep- 
tor-specific distribution than does dystrophin (Chen et al., 
1990; Peng and Chen, 1992). Similarly, syntrophin localizes 
both to focal adhesions and to spontaneously occurring acetyl- 
choline receptor clusters  in  the Xenopus cells, but dystrophin 
localizes only to the focal adhesions (Kramarcy and Sealock, 
1990). In  the mdx  mouse, syntrophin incorporation on the gen- 
eral sarcolemma is decreased relative to normal muscle, but 
the protein remains concentrated at  the neuromuscular junc- 
tion (Butler et al., 1992), which is known to contain dystrophin- 
related protein or proteins, including utrophin  (Fardeau et al., 
1990;  Ohlendieck et al., 1991; Bewick et al., 1993). Thus, there 
must be one or more non-dystrophin-binding proteins for syn- 
trophin in muscle and,  in particular, at acetylcholine receptor 
clusters. Any  of the CRCT-containing proteins discussed here 
are possibilities, although since utrophin has been  shown to be 
a component of the receptor-rich domains at the junction (Be- 
wick et al., 1993), it would appear to be a leading candidate. 
The existence and tissue distribution of the 71K founder 
sequence protein were originally demonstrated using the  anti- 
body  MANDRAl (Lederfein et al., 1992; Hugnot et al., 1992). 
This antibody does not distinguish forms  which  differ in 
COOH-terminal sequence (see Fig. 11, so that these  initial re- 
sults could have included forms with the dystrophin COOH- 
terminal sequence. Using an antibody against  the COOH-ter- 
minal peptide of the founder sequence, we have shown that 
syntrophin-associated founder sequence-like 71K proteins do 
exist in  substantial  quantities in most tissues. Using antibody 
DYS2, against  the  last 17 amino acids of dystrophin, we found 
even larger amounts of syntrophin-associated 7lK-like pro- 
teins which retain the dystrophin COOH-terminal sequence. 
This subfamily appears to have more members than  the sub- 
family having the alternative COOH-terminal sequence (see 
Fig.  3C and accompanying discussion in “Results”). This result 
has  the interesting implication that retention of the penulti- 
mate exon  allows fuller expression of alternative splicing 
events in CT. 
No direct experiment has yet revealed the functional role or 
importance of syntrophin at the cellular or organismal level. 
However, in the mdx3Cv mouse, a single point mutation in 
intron 65 of the dystrophin gene causes truncation and failure 
of expression of normal dystrophin and of normal 71K-like 
proteins of both subfamilies (Cox et al., 1993). In addition to 
suffering from the skeletal and cardiac muscular dystrophy 
characteristic of the mdx  mouse, the mdx3Cv  mouse  produces a 
reduced number of progeny and  has a strikingly reduced neo- 
natal survival rate. Cox et al. (1993) concluded that  the absence 
of the 71K proteins is the probable cause of this phenotype. 
This would also implicate syntrophin, since binding of syntro- 
phin and membrane association are  the only  known activities 
of the 71K proteins. 
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